[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-359168-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-359168-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","hif-activated-priming-of-trail-induced-cell-death-determines-epigenetic-vulnerability-in-kidney-cancer","HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer","","Activation of hypoxia-inducible factors (HIFs) supports cancer cell survival, yet HIF-driven control of cell death is unclear in ccRCC. Cell viability screens identify SGI1027 and MS1129 as HIF-1/2-dependent inducers that selectively kill VHL-deficient ccRCC cells in vitro and patient-derived xenografts in mice. Mechanistically, these compounds trigger proteasomal degradation of DNMT1/3A/3B, causing loss of promoter methylation and induction of TRAIL/DR4/DR5. HIF-1/2 also induces procaspase-10 to commit to TRAIL-mediated apoptosis, and recombinant TRAIL synergizes in vivo, revealing a therapeutic epigenetic vulnerability.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/hif-activated-priming-of-trail-induced-cell-death-determines-epigenetic-vulnerability-in-kidney-cancer/359168/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/hif-activated-priming-of-trail-induced-cell-death-determines-epigenetic-vulnerability-in-kidney-cancer/359168.png","ImageObject",300,407,{"name":42,"@type":43},"Margaret","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role does HIF activation play in VHL-deficient ccRCC cell death?","Question",{"text":63,"@type":64},"HIF-1/2 activation primes VHL-deficient ccRCC cells for apoptosis by transcriptionally inducing procaspase-10, which commits the cells to TRAIL-induced apoptosis after treatment.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do SGI1027 and MS1129 selectively induce death in VHL-deficient ccRCC?",{"text":68,"@type":64},"They induce HIF-1/2-dependent cell death by promoting proteasomal degradation of DNMT1/DNMT3A/DNMT3B, leading to loss of promoter methylation and upregulation of TRAIL, DR4, and DR5.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is combining dDNMT with TRAIL important for therapeutic effects?",{"text":72,"@type":64},"Combining DNMT-targeting compounds (e.g., SGI1027/MS1129) with recombinant TRAIL produces robust, selective apoptosis in VHL-deficient ccRCC models in mice, showing synergistic antitumor activity.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},359168,1790146138,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":99,"preview_page_count":33,"preview_urls":145},137451207643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Article  \nHIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer  \nGraphical abstract  \nHighlights  \n• In vitro chemical screens identify dDNMT as a synthetically lethal partner with VHL loss  \nAuthors  \nYong Wang, Yan Xiong, Shuiqiao Liu, ..., Jian Jin, Yingfei Wang, Weibo Luo  \nCorrespondence  \n[yingfei.wang@utsouthwestern.edu](yingfei.wang@utsouthwestern.edu)[ ](yingfei.wang@utsouthwestern.edu)(Y.W.),  \n[weibo.luo@utsouthwestern.edu](weibo.luo@utsouthwestern.edu) (W.L.)  \nIn brief  \nWang et al. demonstrate that HIF activation in VHL-deficient ccRCC cells primes tumor cells for apoptosis by transcriptionally inducing procaspase- 10. DNMT protein degradation by dDNMT unmasks TRAIL signaling, triggering caspase-10-dependent apoptosis. Combining dDNMT with recombinant TRAIL induces robust, selective apoptosis in patient-derived VHLdeficient ccRCC models, revealing an actionable epigenetic vulnerability.  \n• dDNMT induces TRAIL-mediated apoptosis in VHL-deficient ccRCC cells  \n• The HIF-caspase-10 axis serves as a commitment point fordDNMT-induced ccRCC cell death  \n• dDNMT and TRAIL act synergistically to kill VHL-deficient ccRCC in vitro and in mice  \nWang et al., 2026, Cell Reports Medicine 7, 102630  \nMarch 17, 2026 © 2026 The Author(s) . Published by Elsevier Inc.  \n[https://doi.org/10.1016/j.xcrm.2026.102630](https://doi.org/10.1016/j.xcrm.2026.102630)  \nll  \nll  \nOPEN ACCESS  \nArticle  \nHIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer  \nYong Wang,1 Yan Xiong,2 Shuiqiao Liu,1 Lei Bao,1 Xing Qiu,2 Ilia Korboukh,2 Xiangyang Song,2  \nVanina Toffessi Tcheuyap,3,4 Sipeng Wu,1 Mingyi Chen,1 James Brugarolas,3,4 Jian Jin,2 Yingfei Wang,1,5,6,* and Weibo Luo1,7,8,*  \n1Department of Pathology, UT Southwestern Medical Center, Dallas, TX 75390, USA  \n2Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences, Oncological Sciences and Neuroscience, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA  \n3Kidney Cancer Program, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390, USA  \n4Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX 75390, USA  \n5Department of Neurology, UT Southwestern Medical Center, Dallas, TX 75390, USA  \n6Peter O’Donnell Jr. Brain Institute, UT Southwestern Medical Center, Dallas, TX 75390, USA  \n7Department of Pharmacology, UT Southwestern Medical Center, Dallas, TX 75390, USA  \n8Lead contact  \n*Correspondence: [yingfei.wang@utsouthwestern.edu](yingfei.wang@utsouthwestern.edu) (Y.W.), [weibo.luo@utsouthwestern.edu](weibo.luo@utsouthwestern.edu) (W. L.) [https://doi.org/10.1016/j.xcrm.2026.102630](https://doi.org/10.1016/j.xcrm.2026.102630)  \nSUMMARY  \nActivation of hypoxia-inducible factors (HIFs) supports cancer cell survival, yet how HIFs govern cell death remains unclear, despite evidence that HIF-1 acts as a tumor suppressor in cell renal cell carcinoma (ccRCC) . Here, we report a cell death-priming role for HIF-1/2 in ccRCC. Through cell viability screens with chemical libraries, we identify SGI1027 and its analog MS1129 as HIF-1/2-dependent cell death inducers that specifically kill VHL-deficient ccRCC cells in vitro and patient-derived xenografts in mice. Mechanistically, SGI1027 and MS1129 induce proteasomal degradation of DNMT1/DNMT3A/DNMT3B proteins, leading to the loss of promoter methylation and subsequent upregulation of TRAIL, DR4, and DR5 in ccRCC cells. HIF-1/2 induces procaspase-10 expression serving a commitment point to activate TRAIL-induced apoptosis in VHL-deficient ccRCC following SGI1027 or MS1129 treatment. Notably, recombinant TRAIL protein synergizes with SGI1027 or MS1129 to kill VHL-deficient ccRCC in mice. Collectively, our study unveils an apoptosis induction strategy that involves hijacking HIFs for ccRCC treatment.  \nINTRODUCTION  \nClear cell ren","cbCailQyIntQlALe","https://ap.wps.com/l/cbCailQyIntQlALe","pdf",15737480,24,"English","# Highlights\n## HIF-activated priming of TRAIL-induced apoptosis in VHL-deficient ccRCC\n## Cell death commitment via HIF-caspase-10 axis\n# Summary\n## Strategy: hijacking HIFs for ccRCC treatment\n# Introduction\n## ccRCC biology and VHL loss\n## HIF functions and unmet need for vulnerabilities","[{\"question\":\"What role does HIF activation play in VHL-deficient ccRCC cell death?\",\"answer\":\"HIF-1/2 activation primes VHL-deficient ccRCC cells for apoptosis by transcriptionally inducing procaspase-10, which commits the cells to TRAIL-induced apoptosis after treatment.\"},{\"question\":\"How do SGI1027 and MS1129 selectively induce death in VHL-deficient ccRCC?\",\"answer\":\"They induce HIF-1/2-dependent cell death by promoting proteasomal degradation of DNMT1/DNMT3A/DNMT3B, leading to loss of promoter methylation and upregulation of TRAIL, DR4, and DR5.\"},{\"question\":\"Why is combining dDNMT with TRAIL important for therapeutic effects?\",\"answer\":\"Combining DNMT-targeting compounds (e.g., SGI1027/MS1129) with recombinant TRAIL produces robust, selective apoptosis in VHL-deficient ccRCC models in mice, showing synergistic antitumor activity.\"}]","HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer | PDF",1790136321,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6fbe941ee6a8d0d4a7fbbe6c94f55e50.webp",983,1276,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/244fb5285015f7534930ea40e8cbc978.webp",982,1275,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3b42230669b7c2b1e08ad344e841c284.webp",981,1273,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c50caaffbc9c8306f4867c54fe438293.webp",980,1272]